These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2433011)

  • 21. [Prenatal serum screening of aneuploidy and of neural tube defects in the second trimester of pregnancy among the population of Luxembourg. Evaluation of risk by the triple test (AFP+THCG+UE3)].
    Thix J
    Bull Soc Sci Med Grand Duche Luxemb; 1997; 134(1):25-9. PubMed ID: 9303823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How much money can early prenatal care for teen pregnancies save?: a cost-benefit analysis.
    Hueston WJ; Quattlebaum RG; Benich JJ
    J Am Board Fam Med; 2008; 21(3):184-90. PubMed ID: 18467529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs and effects of prenatal screening methods for Down syndrome and neural tube defects.
    Hoogendoorn M; Evers SM; Schielen PC; van Genugten ML; de Wit GA; Ament AJ
    Community Genet; 2008; 11(6):359-67. PubMed ID: 18690004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triploidy identified through second-trimester serum screening.
    Huang T; Alberman E; Wald N; Summers AM
    Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cost-benefit analysis of screening for congenital toxoplasmosis].
    Sagmeister M; Gessner U; Kind C; Horisberger B
    Schweiz Med Wochenschr Suppl; 1995; 65():103S-112S. PubMed ID: 7716447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prenatal testing for maternal serum alpha-fetoprotein.
    Schwager EJ; Weiss BD
    Am Fam Physician; 1987 Apr; 35(4):169-74. PubMed ID: 2436465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maternal serum alpha-fetoprotein screening: a cost-benefit analysis.
    Layde PM; von Allmen SD; Oakley GP
    Am J Public Health; 1979 Jun; 69(6):566-73. PubMed ID: 87134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preconception care: preliminary estimates of costs and effects of smoking cessation and folic acid supplementation.
    de Weerd S; Polder JJ; Cohen-Overbeek TE; Zimmermann LJ; Steegers EA
    J Reprod Med; 2004 May; 49(5):338-44. PubMed ID: 15214705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maternal serum alpha-fetoprotein screening for Down syndrome: economic considerations.
    Swint JM; Greenberg F
    Am J Med Genet; 1988 Sep; 31(1):231-45. PubMed ID: 2464933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using record linkage and manual follow-up to evaluate the Victorian maternal serum screening quadruple test for Down's syndrome, trisomy 18 and neural tube defects.
    Jaques AM; Collins VR; Haynes K; Sheffield LJ; Francis I; Forbes R; Halliday JL
    J Med Screen; 2006; 13(1):8-13. PubMed ID: 16569299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness of prenatal serum biomarker screening for neural tube defects in second trimester pregnant women: a meta-analysis.
    Wang ZP; Li H; Hao LZ; Zhao ZT
    Prenat Diagn; 2009 Oct; 29(10):960-5. PubMed ID: 19609892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated maternal serum alpha-fetoprotein with normal ultrasound: is amniocentesis always appropriate? A review of 26,069 screened patients.
    Richards DS; Seeds JW; Katz VL; Lingley LH; Albright SG; Cefalo RC
    Obstet Gynecol; 1988 Feb; 71(2):203-7. PubMed ID: 2447540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Informing policy for the Australian context - Costs, outcomes and cost savings of prenatal carrier screening for cystic fibrosis.
    Maxwell S; Brameld K; Youngs L; Geelhoed E; O'Leary P
    Aust N Z J Obstet Gynaecol; 2010 Feb; 50(1):51-9. PubMed ID: 20218998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prenatal diagnosis policy without routine amniocentesis in pregnancies with a positive family history for neural tube defects.
    Papp Z; Tóth Z; Török O; Szabó M
    Am J Med Genet; 1987 Jan; 26(1):103-10. PubMed ID: 2433941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening.
    Norem CT; Schoen EJ; Walton DL; Krieger RC; O'Keefe J; To TT; Ray GT
    Obstet Gynecol; 2005 Oct; 106(4):747-52. PubMed ID: 16199631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maternal serum alpha-fetoprotein screening: report of a Canadian pilot project.
    Doran TA; Valentine GH; Wong PY; Wielgosz G; Benzie RJ; Soltan HC; Jenner MR; Morland PA; Montgomery RJ; Allen LC
    CMAJ; 1987 Aug; 137(4):285-93. PubMed ID: 2440547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome.
    Shackley P; McGuire A; Boyd PA; Dennis J; Fitchett M; Kay J; Roche M; Wood P
    J Public Health Med; 1993 Jun; 15(2):175-84. PubMed ID: 7688977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential and contingent prenatal screening for Down syndrome.
    Wald NJ; Rudnicka AR; Bestwick JP
    Prenat Diagn; 2006 Sep; 26(9):769-77. PubMed ID: 16821246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-fetoprotein detection of neural tube defects and the impact of standard ultrasound.
    Dashe JS; Twickler DM; Santos-Ramos R; McIntire DD; Ramus RM
    Am J Obstet Gynecol; 2006 Dec; 195(6):1623-8. PubMed ID: 16769022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maternal serum screening for birth defects: results of a Connecticut regional program.
    Benn PA; Horne D; Craffey A; Collins R; Ramsdell L; Greenstein R
    Conn Med; 1996 Jun; 60(6):323-7. PubMed ID: 8706425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.